196 related articles for article (PubMed ID: 8490080)
21. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Multicentre Investigational Group.
Robinson M; Sahba B; Avner D; Jhala N; Greski-Rose PA; Jennings DE
Aliment Pharmacol Ther; 1995 Feb; 9(1):25-31. PubMed ID: 7766740
[TBL] [Abstract][Full Text] [Related]
22. Factors affecting quality of ulcer healing after lansoprazole treatment.
Ito G; Nakagawara M; Watanabe F; Ooi S; Nawano M; Hanai H; Kaneko E
J Clin Gastroenterol; 1995; 20 Suppl 2():S62-6. PubMed ID: 7594344
[TBL] [Abstract][Full Text] [Related]
23. Long-term omeprazole treatment in man: effects on gastric endocrine cell populations.
Lamberts R; Creutzfeldt W; Stöckmann F; Jacubaschke U; Maas S; Brunner G
Digestion; 1988; 39(2):126-35. PubMed ID: 3410169
[TBL] [Abstract][Full Text] [Related]
24. A comparison of three doses of lansoprazole (15, 30 and 60 mg) and placebo in the treatment of duodenal ulcer. The Lansoprazole Study Group.
Avner DL; Dorsch ER; Jennings DE; Greski-Rose PA
Aliment Pharmacol Ther; 1995 Oct; 9(5):521-8. PubMed ID: 8580272
[TBL] [Abstract][Full Text] [Related]
25. Lansoprazole is superior to ranitidine as maintenance treatment for the prevention of duodenal ulcer relapse.
Bardhan KD; Crowe J; Thompson RP; Trewby PN; Keeling PN; Weir D; Crouch SL
Aliment Pharmacol Ther; 1999 Jun; 13(6):827-32. PubMed ID: 10383514
[TBL] [Abstract][Full Text] [Related]
26. Rabeprazole: an update of its use in acid-related disorders.
Carswell CI; Goa KL
Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
[TBL] [Abstract][Full Text] [Related]
27. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine.
Hawkey CJ; Long RG; Bardhan KD; Wormsley KG; Cochran KM; Christian J; Moules IK
Gut; 1993 Oct; 34(10):1458-62. PubMed ID: 8244121
[TBL] [Abstract][Full Text] [Related]
28. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Poynard T; Lemaire M; Agostini H
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
[TBL] [Abstract][Full Text] [Related]
29. Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Lazzaroni M; Bargiggia S; Bianchi Porro G
Am J Gastroenterol; 1997 Apr; 92(4):649-52. PubMed ID: 9128316
[TBL] [Abstract][Full Text] [Related]
30. [Lansoprazole--profile of a new proton pump inhibitor].
Seifert E
Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of lansoprazole in eradication of Helicobacter pylori.
Katoh M; Asaka M; Kudoh M; Kagaya H; Katagiri M; Takeda H
J Clin Gastroenterol; 1995; 20 Suppl 2():S112-4. PubMed ID: 7594324
[TBL] [Abstract][Full Text] [Related]
33. Lansoprazole versus omeprazole for duodenal ulcer healing and prevention of relapse: a randomized, multicenter, double-masked trial.
Dobrilla G; Piazzi L; Fiocca R
Clin Ther; 1999 Aug; 21(8):1321-32. PubMed ID: 10485504
[TBL] [Abstract][Full Text] [Related]
34. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Richter JE; Campbell DR; Kahrilas PJ; Huang B; Fludas C
Arch Intern Med; 2000 Jun; 160(12):1803-9. PubMed ID: 10871974
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of lansoprazole in the treatment of peptic ulcers: initial healing and prevention of relapse. Tohoku Peptic Ulcer Study Group.
Asaki S; Sato A; Sakurada H; Takeda T; Hongo M; Toyota T
J Clin Gastroenterol; 1995; 20 Suppl 2():S56-8. PubMed ID: 7594342
[TBL] [Abstract][Full Text] [Related]
36. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Florent C
Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
[TBL] [Abstract][Full Text] [Related]
37. The effect of lansoprazole treatment on the healing and relapse of peptic ulcer and serum levels of IgG anti-Helicobacter pylori antibody.
Mine T; Yasuda H; Akimoto K; Katoaka A; Mashima H; Tajima A; Fukujin H; Tsuchida T; Takano T; Nagasawa J
J Clin Gastroenterol; 1995; 20 Suppl 2():S75-8. PubMed ID: 7594347
[TBL] [Abstract][Full Text] [Related]
38. The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Jhala NC; McFarland MM; Brightman SA; Morale B; Rubin W; Atkinson BF
Am J Gastroenterol; 1995 Oct; 90(10):1824-8. PubMed ID: 7572902
[TBL] [Abstract][Full Text] [Related]
39. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Tolia V; Fitzgerald J; Hassall E; Huang B; Pilmer B; Kane R
J Pediatr Gastroenterol Nutr; 2002; 35 Suppl 4():S300-7. PubMed ID: 12607790
[TBL] [Abstract][Full Text] [Related]
40. Lansoprazole: a comprehensive review.
Zimmermann AE; Katona BG
Pharmacotherapy; 1997; 17(2):308-26. PubMed ID: 9085323
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
